The Contemporary History of the drug therapy in patients with arterial hypertension: is antihypertensive therapy only one way of treating?

Cover Page

Cite item

Full Text

Abstract

This article discusses the results of the recently concluded randomized and observational studies, which may significantly affect application of antihypertensive and lipid-lowering agents as well as may affect application of combined agents containing constant doses of drugs having an effect on blood pressure and blood lipid concentrations. We showed new data concerning the best approaches to use statins for the purpose of primary prevention. We discussed the possible changes for target arterial pressure and probably for threshold level of arterial pressure in a wide range of patients suffering from arterial hypertension. We discussed the role of new combined drug called Ekvamer, containing constant doses of amlodipine, lisinopril and rosuvastatin, to reduce the risk of cardiovascular disease complications associated with atherosclerosis.

About the authors

S. R Giliarevskii

Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation

Email: sgilarevsky@rambler.ru
д-р мед. наук, проф. каф. клинической фармакологии и терапии ГБОУ ДПО РМАПО 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1

M. V Golshmid

Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation

канд. мед. наук, доц. каф. клин. фармакологии и терапии ГБОУ ДПО РМАПО 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1

I. M Kuzmina

N.V.Sklifosovsky Research Institute of Emergency Medicine of the Department of Health of Moscow

канд. мед. наук, вед. науч. сотр. отд-ния неотложной кардиологии ГБУЗ НИИ СП им. Н.В.Склифосовского 129090, Russian Federation, Mosсow, Bol’shaya Sukharevskaya pl., d. 3

G. Yu Zakharova

Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation

канд. мед. наук, доц. каф. клин. фармакологии и терапии ГБОУ ДПО РМАПО 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1

I. I Sinitsina

Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation

д-р мед. наук, проф. каф. клин. фармакологии и терапии ГБОУ ДПО РМАПО 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1

References

  1. Roth G.A, Forouzanfar M.H, Moran A.E et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med 2015; 372: 1333-41.
  2. Lewington S, Clarke R, Qizilbash N et al. Age - specific relevance of usual blood pressure to vascular mortality: a meta - analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.
  3. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case - control study. Lancet 2004; 364: 937-52.
  4. Rose G. Strategy of prevention: lessons from cardiovascular disease. Br Med J (Clin Res Ed) 1981; 282: 1847-51.
  5. Wald N.J, Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419.
  6. Yusuf S, Lonn E, Pais P et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. NEJM 2016, April 2.
  7. The SPRINT Research Group. A randomized trial of intensive versus standard blood - pressure control. N Engl J Med 2015; 373: 2103-16.
  8. Lonn E.M, Bosch J, Lopez-Jaramillo P et al. Blood - pressure lowering in intermediate - risk persons without cardiovascular disease. N Engl J Med. DOI: 10.1056/ NEJ- Moa1600175
  9. Emdin C.A, Rahimi K, Neal B et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta - analysis. JAMA 2015; 313: 603-15.
  10. Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta - analyses. BMJ 2016; 352: i717.
  11. Stone N.J, Robinson J.G, Lichtenstein A.H et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation 2014; 129 (25, Suppl. 2): S1-S45.
  12. Perk J, De Backer G, Gohlke H et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635-701.
  13. Goff D.C.Jr, Lloyd-Jones D.M, Bennett G et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2935-59.
  14. National Institute for Health and Care Excellence (NICE). Clinical Guideline CG181: lipid modification - cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. http://www.nice.org.uk/Guidance/cg181
  15. JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014; 100: ii1-67.
  16. Lloyd-Jones D.M. Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation 2010; 121: 1768-77.
  17. Cooney M.T, Dudina A.L, Graham I.M. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. J Am Coll Cardiol 2009; 54: 1209-27.
  18. Ridker P.M, Wilson P.W. A trial - based approach to statin guidelines. JAMA 2013; 310: 1123-4.
  19. Ridker P.M, Rose L, Cook .. A Proposal to incorporate trial data into a hybrid ACC/AHA algorithm for the allocation of statin therapy in primary prevention. J Am Coll Cardiol 2015; 65: 942-8.
  20. Mortensen M.B, Afzal S, Nordestgaard B.G, Falk E. Primary Prevention With Statins: ACC/AHA Risk-Based Approach Versus Trial-Based Approaches to Guide Statin Therapy. J Am Coll Cardiol 2015; 66: 2699-709.
  21. Jones P.H, Davidson M.H, Stein E.A et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152-60.
  22. Mc Kenney J.M, Jones P.H, Adamczyk M.A et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003; 19: 689-98.
  23. Nicholls S.J, Ballantyne C.M, Barter P.J et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011; 365: 2078-87.
  24. Cannon C.P, Blazing M.A, Giugliano R.P et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372: 2387-97.
  25. Jaffe M.G, Lee G.A, Young J.D et al. Improved blood pressure control associated with a largescale hypertension program. JAMA 2013; 310: 699-705.
  26. Kotchen T.A. Expanding role for combination drug therapy in the initial treatment of hypertension? Hypertension 2011; 58: 550-1.
  27. Tomaszewski M, White C, Patel P et al. High rates of non - adherence to antihypertensive treatment revealed by high - performance liquid chromatography - tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 2014; 100 (11): 855-61.
  28. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies